Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Repare Therapeutics stock | $37.11

Own Repare Therapeutics stock in just a few minutes.

Fact checked

Repare Therapeutics Inc is a biotechnology business based in the US. Repare Therapeutics shares (RPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Repare Therapeutics employs 79 staff and has a market cap (total outstanding shares value) of USD$1.3 billion.

How to buy shares in Repare Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Repare Therapeutics. Find the stock by name or ticker symbol: RPTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Repare Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$37.11, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Repare Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Repare Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Repare Therapeutics share price

Use our graph to track the performance of RPTX stocks over time.

Repare Therapeutics shares at a glance

Information last updated 2020-12-03.
Latest market closeUSD$37.11
52-week rangeUSD$21.45 - USD$36.67
50-day moving average USD$27.818
200-day moving average USD$27.239
Wall St. target priceUSD$36.8
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.1103

Buy Repare Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Repare Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Repare Therapeutics price performance over time

Historical closes compared with the close of $37.11 from 2020-12-09

1 week (2021-01-08) -12.89%
1 month (2020-12-15) -0.40%
3 months (2020-10-15) 52.15%
6 months (2020-07-15) 64.79%
1 year (2020-01-12) N/A
2 years (2019-01-12) N/A
3 years (2018-01-12) N/A
5 years (2016-01-12) N/A

Repare Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$1.3 billion

TTM: trailing 12 months

Shorting Repare Therapeutics shares

There are currently 899,287 Repare Therapeutics shares held short by investors – that's known as Repare Therapeutics's "short interest". This figure is 5.6% up from 851,982 last month.

There are a few different ways that this level of interest in shorting Repare Therapeutics shares can be evaluated.

Repare Therapeutics's "short interest ratio" (SIR)

Repare Therapeutics's "short interest ratio" (SIR) is the quantity of Repare Therapeutics shares currently shorted divided by the average quantity of Repare Therapeutics shares traded daily (recently around 101959.97732426). Repare Therapeutics's SIR currently stands at 8.82. In other words for every 100,000 Repare Therapeutics shares traded daily on the market, roughly 8820 shares are currently held short.

However Repare Therapeutics's short interest can also be evaluated against the total number of Repare Therapeutics shares, or, against the total number of tradable Repare Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Repare Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Repare Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0589% of the tradable shares (for every 100,000 tradable Repare Therapeutics shares, roughly 59 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Repare Therapeutics.

Find out more about how you can short Repare Therapeutics stock.

Repare Therapeutics share dividends

We're not expecting Repare Therapeutics to pay a dividend over the next 12 months.

Repare Therapeutics overview

Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing CCNE1-SL inhibitor, a proprietary drug discovery program for tumors with amplification of CCNE1; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was founded in 2016 and is headquartered in Montréal, Canada.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site